stock.name

Halozyme Therapeutics Inc.

HALO

Market Cap$5.11B
Close$

Compare Halozyme Therapeutics

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Halozyme Therapeutics Inc.Halozyme Therapeutics Inc.18.10%336%6.817.9
marketMarket Avg59.61.27%31%6.41
HealthcareHealthcare Avg62.31.27%15%7.30.9
$40.89

Current Fair Value

0.4% upside

Undervalued by 0.4% based on the discounted cash flow analysis.

Share Statistics

Market cap$5.11 Billion
Enterprise Value$6.27 Billion
Dividend Yield$0.0 (0.0%)
Earnings per Share$2.1
Beta0.98
Outstanding Shares127,054,240
Avg 30 Day Volume1,134,450

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio18.15
PEG37.82
Price to Sales6.79
Price to Book Ratio-
Enterprise Value to Revenue7.57
Enterprise Value to EBIT18.58
Enterprise Value to Net Income22
Total Debt to Enterprise0.24
Debt to Equity17.89

Revenue Sources

No data

ESG Score

No data

About Halozyme Therapeutics Inc.

CEO: Helen Torley